What does a high-profile dinner between political juggernauts look like? Elaborate ceremonies, glitz and glamour, a fancy spread and at least the impression of progress toward aligned geopolitical goals. Add a sprinkle of tech moguls to the broth and the conversation could get spicy. The Long View previously spoke about “doomsayers” and the threat of AI to humanity — so at least the dinner guests have something to talk about. The Long View hates awkward silences too.
This week, US president Donald Trump hosted his Chinese counterpart Xi Jinping at a state dinner. Miles away in London, the biopharma industry was having its own version of a tense dinner with conversations centred on China's growing role in global drug development.
Partner Or Rival
China’s share of big pharma licensing deals valued at $50m or more has been transformed, from just 5% in 2021 to 39% last year, according to a July J.P. Morgan biopharma report. The trend has continued in the first six months of this year, with China-origin assets reaching 42% of deals and representing 68% of the upfront dollars across these transactions.